Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension.
暂无分享,去创建一个
[1] W. Chung,et al. [Genetics and genomics of pulmonary arterial hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[2] N. Morrell,et al. TGF-beta and BMPR-II pharmacology--implications for pulmonary vascular diseases. , 2009, Current opinion in pharmacology.
[3] L. Farkas,et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. , 2009, The Journal of clinical investigation.
[4] C. Hoppel,et al. New aspects of impaired mitochondrial function in heart failure , 2009, Journal of bioenergetics and biomembranes.
[5] G. Noon,et al. Acquired Genetic Abnormalities in the Lungs of Patients with Pulmonary Arterial Hypertension. , 2009, ATS 2009.
[6] M. Myers. Moonlighting in Mitochondria , 2009, Science.
[7] P. Fawcett,et al. Function of Mitochondrial Stat3 in Cellular Respiration , 2009, Science.
[8] A. Bracht,et al. Effects of monocrotaline on energy metabolism in the rat liver. , 2008, Toxicology letters.
[9] A. Arroliga,et al. Deficiency of Lung Antioxidants in Idiopathic Pulmonary Arterial Hypertension , 2008, Clinical and translational science.
[10] P. Fortina,et al. Hearts lacking caveolin-1 develop hypertrophy with normal cardiac substrate metabolism , 2008, Cell cycle.
[11] L. Oberley,et al. Manganese superoxide dismutase modulates hypoxia-inducible factor-1 alpha induction via superoxide. , 2008, Cancer research.
[12] P. Sehgal,et al. Cytoplasmic provenance of STAT3 and PY-STAT3 in the endolysosomal compartments in pulmonary arterial endothelial and smooth muscle cells: implications in pulmonary arterial hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[13] S. Erzurum,et al. Copyright © American Society for Investigative Pathology DOI: 10.2353/ajpath.2008.070705 Cardiovascular, Pulmonary and Renal Pathology Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension , 2022 .
[14] M. Maitland,et al. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. , 2008, American journal of physiology. Heart and circulatory physiology.
[15] P. Oliveira,et al. Diabetes and the impairment of reproductive function: possible role of mitochondria and reactive oxygen species. , 2008, Current diabetes reviews.
[16] M. Rabinovitch. Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.
[17] Thomas F. Rau,et al. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[18] W. Chung,et al. Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA(Leu) gene (m.3243A>G) , 2008, Journal of Inherited Metabolic Disease.
[19] J. Darnell,et al. SnapShot: JAK-STAT Signaling , 2007, Cell.
[20] N. Chandel,et al. Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis , 2007, Molecular and Cellular Biology.
[21] G. Semenza,et al. Life with Oxygen , 2007, Science.
[22] S. Erzurum,et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[23] P. Sehgal,et al. Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[24] R. Tuder,et al. Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.
[25] Raed A Dweik,et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.
[26] S. Wedgwood,et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.
[27] M. Lisanti,et al. Short-Term Administration of a Cell-Permeable Caveolin-1 Peptide Prevents the Development of Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy , 2006, Circulation.
[28] Oksana Gavrilova,et al. p53 Regulates Mitochondrial Respiration , 2006, Science.
[29] S. Archer,et al. An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary Arterial Hypertension , 2006, Circulation.
[30] Ken Garber,et al. Energy Deregulation: Licensing Tumors to Grow , 2006, Science.
[31] S. Moncada,et al. Mitochondria as signaling organelles in the vascular endothelium. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[32] T. Stevens. Molecular and cellular determinants of lung endothelial cell heterogeneity. , 2005, Chest.
[33] A. Zaiman,et al. One hundred years of research in the pathogenesis of pulmonary hypertension. , 2005, American journal of respiratory cell and molecular biology.
[34] E. Clementi,et al. Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. , 2005, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[35] G. Semenza,et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.
[36] Jung Weon Lee,et al. The FASEB Journal express article 10.1096/fj.04-3099fje. Published online May 26, 2005. ©2005 FASEB , 2022 .
[37] G. Diette,et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. , 2005, American journal of respiratory and critical care medicine.
[38] N. Voelkel,et al. Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] T. Jacques,et al. Pulmonary Hypertension in a GTP-Cyclohydrolase 1–Deficient Mouse , 2005, Circulation.
[40] K. Rockett,et al. Pivotal Role for Endothelial Tetrahydrobiopterin in Pulmonary Hypertension , 2005, Circulation.
[41] S. Schreiber,et al. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] A. Vinogradov,et al. Generation of superoxide-radical by the NADH: Ubiquinone oxidoreductase of heart mitochondria , 2005, Biochemistry (Moscow).
[43] R. Ahmed. The Physiological and Biochemical Effects of Diabetes on the Balance between Oxidative Stress and Antioxidant Defense System , 2005 .
[44] Enrique Cadenas,et al. On the mechanism and biology of cytochrome oxidase inhibition by nitric oxide. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[45] E. Clementi,et al. Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[46] A. Tanswell,et al. Peroxynitrite inhibits relaxation and induces pulmonary artery muscle contraction in the newborn rat. , 2004, Free radical biology & medicine.
[47] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[48] S. Hazen,et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] A. Arroliga,et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. , 2004, Free radical biology & medicine.
[50] G. Nickenig,et al. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. , 2004, Hypertension.
[51] P. Sehgal,et al. Disruption of Endothelial-Cell Caveolin-1&agr;/Raft Scaffolding During Development of Monocrotaline-Induced Pulmonary Hypertension , 2004, Circulation.
[52] V. Borutaite,et al. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. , 2004, Biochimica et biophysica acta.
[53] P. Singal,et al. Antioxidant and oxidative stress changes in experimental cor pulmonale , 2004, Molecular and Cellular Biochemistry.
[54] M. Goligorsky,et al. Docking of Endothelial Nitric Oxide Synthase (eNOS) to the Mitochondrial Outer Membrane , 2004, Journal of Biological Chemistry.
[55] N. Voelkel,et al. Oxidative stress in severe pulmonary hypertension. , 2004, American journal of respiratory and critical care medicine.
[56] N. Alp,et al. Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[57] A. Biondi,et al. Methods to detect mitochondrial function , 2004, Experimental Gerontology.
[58] Troy Stevens,et al. Structural and functional characteristics of lung macro- and microvascular endothelial cell phenotypes. , 2004, Microvascular research.
[59] W. Bottje,et al. Investigation of proton conductance in liver mitochondria of broilers with pulmonary hypertension syndrome. , 2004, Poultry science.
[60] Thilo Hagen,et al. Redistribution of Intracellular Oxygen in Hypoxia by Nitric Oxide: Effect on HIF1α , 2003, Science.
[61] M. Murphy. Does interplay between nitric oxide and mitochondria affect hypoxia-inducible transcription factor-1 activity? , 2003, The Biochemical journal.
[62] S. Wedgwood,et al. Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension. , 2003, Antioxidants & redox signaling.
[63] S. Moncada,et al. Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. , 2003, The Biochemical journal.
[64] J. Nichols,et al. BMP Induction of Id Proteins Suppresses Differentiation and Sustains Embryonic Stem Cell Self-Renewal in Collaboration with STAT3 , 2003, Cell.
[65] K. Sayama,et al. Nuclear Translocation of Phosphorylated STAT3 Is Essential for Vascular Endothelial Growth Factor-induced Human Dermal Microvascular Endothelial Cell Migration and Tube Formation* , 2003, Journal of Biological Chemistry.
[66] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[67] M. Bartoli,et al. VEGF differentially activates STAT3 in microvascular endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] M. Wick,et al. Peroxisome Proliferator-Activated Receptor Gamma (PPAR&ggr;) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth , 2003, Circulation research.
[69] P. Carmeliet,et al. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. , 2003, The Journal of clinical investigation.
[70] A. Yoshimura,et al. Inhibition of STAT3 prevents neointima formation by inhibiting proliferation and promoting apoptosis of neointimal smooth muscle cells. , 2003, Human gene therapy.
[71] W. Aird. Endothelial cell heterogeneity , 2003, Critical care medicine.
[72] E. Clementi,et al. Mitochondrial Biogenesis in Mammals: The Role of Endogenous Nitric Oxide , 2003, Science.
[73] S. Iwata,et al. Architecture of Succinate Dehydrogenase and Reactive Oxygen Species Generation , 2003, Science.
[74] M. Pelletier,et al. Mechanisms involved in interleukin‐15‐induced suppression of human neutrophil apoptosis: role of the anti‐apoptotic Mcl‐1 protein and several kinases including Janus kinase‐2, p38 mitogen‐activated protein kinase and extracellular signal‐regulated kinases‐1/2 , 2002, FEBS letters.
[75] A. Ramachandran,et al. Mitochondria, nitric oxide, and cardiovascular dysfunction. , 2002, Free radical biology & medicine.
[76] X. Bigard,et al. Endothelial nitric oxide synthase (NOS) deficiency affects energy metabolism pattern in murine oxidative skeletal muscle. , 2002, The Biochemical journal.
[77] N. Morrell,et al. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. , 2002, Progress in cardiovascular diseases.
[78] T. Giles,et al. Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[79] J. Ross,et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[80] S. Erzurum,et al. Antioxidant responses to oxidant-mediated lung diseases. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[81] W. Bottje,et al. Heart and breast muscle mitochondrial dysfunction in pulmonary hypertension syndrome in broilers (Gallus domesticus). , 2002, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.
[82] D. Aaronson,et al. A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.
[83] R. Trembath,et al. Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.
[84] F. Beyersdorf,et al. Successful treatment of pulmonary hypertension with inhaled nitric oxide after pulmonary embolectomy. , 2002, The Annals of thoracic surgery.
[85] Jorge D. Erusalimsky,et al. Does nitric oxide modulate mitochondrial energy generation and apoptosis? , 2002, Nature Reviews Molecular Cell Biology.
[86] J. Dyck,et al. Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels , 2002, Circulation.
[87] K. Ozawa,et al. Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. , 2002 .
[88] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[89] K. Yasuda,et al. A Defect in the Cytochrome b Large Subunit in Complex II Causes Both Superoxide Anion Overproduction and Abnormal Energy Metabolism in Caenorhabditis elegans * , 2001, The Journal of Biological Chemistry.
[90] G. Christ,et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. , 2001, The Journal of biological chemistry.
[91] G. Semenza,et al. Expression of angiogenesis‐related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis , 2001, The Journal of pathology.
[92] J. Cracowski,et al. Increased lipid peroxidation in patients with pulmonary hypertension. , 2001, American journal of respiratory and critical care medicine.
[93] Z. Katusic. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? , 2001, American journal of physiology. Heart and circulatory physiology.
[94] R. Gascoyne,et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. , 2001, Blood.
[95] R. Wideman,et al. Lung mitochondrial dysfunction in pulmonary hypertension syndrome. II. Oxidative stress and inability to improve function with repeated additions of adenosine diphosphate. , 2001, Poultry science.
[96] R. Wideman,et al. Lung mitochondrial dysfunction in pulmonary hypertension syndrome. I. Site-specific defects in the electron transport chain. , 2001, Poultry science.
[97] E. Werner,et al. Reactive Oxygen Species Mediate Endothelium-Dependent Relaxations in Tetrahydrobiopterin-Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[98] N. Voelkel,et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. , 2001, Journal of applied physiology.
[99] P. Hirth,et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[100] N. Voelkel,et al. Microsatellite Instability of Endothelial Cell Growth and Apoptosis Genes Within Plexiform Lesions in Primary Pulmonary Hypertension , 2001, Circulation research.
[101] A. Arroliga,et al. High Levels of Nitric Oxide in Individuals with Pulmonary Hypertension Receiving Epoprostenol Therapy , 2001, Lung.
[102] M. Ebaid,et al. Effects of Low Doses of Inhaled Nitric Oxide Combined with Oxygen for the Evaluation of Pulmonary Vascular Reactivity in Patients with Pulmonary Hypertension , 2001, Pediatric Cardiology.
[103] B. Fanburg,et al. Reactive oxygen species in cell signaling. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[104] S. Rich,et al. Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". , 2000, Circulation.
[105] M. Humbert,et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.
[106] M. Kizaki,et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. , 2000, Blood.
[107] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.
[108] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[109] Y. Fujio,et al. Signal Transducer and Activator of Transcription 3 Is Required for Glycoprotein 130-mediated Induction of Vascular Endothelial Growth Factor in Cardiac Myocytes* , 2000, The Journal of Biological Chemistry.
[110] T. McCaffrey. TGF-s and TGF- receptors in atherosclerosis , 2000 .
[111] A. Eckhardt,et al. A possible role of the oxidant tissue injury in the development of hypoxic pulmonary hypertension. , 2000, Physiological research.
[112] T. McCaffrey. TGF-betas and TGF-beta receptors in atherosclerosis. , 2000, Cytokine & growth factor reviews.
[113] P. Cacoub,et al. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. , 1999, Cardiovascular research.
[114] R. L. Williams,et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. , 1999, The American journal of pathology.
[115] S. Moncada. Nitric oxide: discovery and impact on clinical medicine , 1999, Journal of the Royal Society of Medicine.
[116] D. Wallace. Mitochondrial diseases in man and mouse. , 1999, Science.
[117] T. Beaty,et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. , 1999, The Journal of clinical investigation.
[118] A. Schapira,et al. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. , 1999, Biochimica et biophysica acta.
[119] K. Bloch,et al. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. , 1999, American journal of physiology. Lung cellular and molecular physiology.
[120] P. Huang,et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. , 1999, The Journal of clinical investigation.
[121] Y. Lai,et al. Antioxidants attenuate chronic hypoxic pulmonary hypertension. , 1998, Journal of cardiovascular pharmacology.
[122] N. Chandel,et al. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[123] A. Arroliga,et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.
[124] N. Voelkel,et al. Primary pulmonary hypertension between inflammation and cancer. , 1998, Chest.
[125] M. Yacoub,et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension , 1998, The Journal of pathology.
[126] G. Semenza,et al. Carbon Monoxide and Nitric Oxide Suppress the Hypoxic Induction of Vascular Endothelial Growth Factor Gene via the 5′ Enhancer* , 1998, The Journal of Biological Chemistry.
[127] D. Stewart,et al. EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. , 1998, Circulation.
[128] K. Shroyer,et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.
[129] D. Laskowski,et al. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. , 1998, The Journal of clinical investigation.
[130] A. Bardelli,et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway , 1998, Nature.
[131] R. Paus,et al. Interleukin-15 protects from lethal apoptosis in vivo , 1997, Nature Medicine.
[132] J. Cooke,et al. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. , 1997, Circulation.
[133] J. Schrader,et al. Energy turnover of vascular endothelial cells. , 1997, The American journal of physiology.
[134] N. Voelkel,et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.
[135] M. Pepper,et al. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. , 1997, Cytokine & growth factor reviews.
[136] A. Beaulieu,et al. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. , 1996, Blood.
[137] J. Poderoso,et al. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. , 1996, Archives of biochemistry and biophysics.
[138] R. Michel,et al. Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. , 1995, Human pathology.
[139] W. Bottje,et al. Effect of alpha-tocopherol on antioxidants, lipid peroxidation, and the incidence of pulmonary hypertension syndrome (ascites) in broilers. , 1995, Poultry science.
[140] A Giaid,et al. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.
[141] N. Voelkel,et al. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.
[142] Carl Nathan,et al. Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.
[143] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[144] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[145] J. Stamler,et al. The biology of nitrogen oxides in the airways. , 1994, American journal of respiratory and critical care medicine.
[146] H. Sies. Strategies of antioxidant defense , 1993 .
[147] L. Ignarro. Nitric Oxide-mediated Vasorelaxation , 1993, Thrombosis and Haemostasis.
[148] O. Griffith,et al. Mammalian nitric oxide synthases. , 1999, Advances in enzymology and related areas of molecular biology.
[149] S. Ogawa,et al. Hypoxia induces glucose transporter expression in endothelial cells. , 1992, The American journal of physiology.
[150] D. Langleben,et al. Effects of dimethylthiourea on chronic hypoxia-induced pulmonary arterial remodelling and ventricular hypertrophy in rats. , 1989, Clinical and investigative medicine. Medecine clinique et experimentale.
[151] C. Nathan,et al. Secretion of pyruvate. An antioxidant defense of mammalian cells , 1987, The Journal of experimental medicine.
[152] J. Singh,et al. Pyruvate and related alpha-ketoacids protect mammalian cells in culture against hydrogen peroxide-induced cytotoxicity. , 1985, Toxicology letters.
[153] J. Foker,et al. Aerobic glycolysis during lymphocyte proliferation , 1976, Nature.
[154] S. Weinhouse. Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes memorial lecture. , 1972, Cancer research.
[155] J. Dobiáš. Histopathology of pulmonary hypertension. , 1972, Acta Universitatis Carolinae. Medica.
[156] J. Edwards,et al. The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects , 1958, Circulation.